Search

Your search keyword '"Mangas, Monserrat"' showing total 19 results
Start Over Author "Mangas, Monserrat"
19 results on '"Mangas, Monserrat"'

1. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

Author

Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martínez de Castro, Eva, Custodio, Ana, Pericay Pijaume, Carles, Hernandez, Raquel, Aguado, Gema, Castro Unanua, Natalia, Cano, Juana María, López, Flora, Garrido, Marcelo, Fernández Montes, Ana, Visa, Laura, Sánchez Cánovas, Manuel, Limón, María Luisa, Martínez Lago, Nieves, Pimentel, Paola, Hurtado, Alicia, Azkárate, Aitor, Longo, Federico, Diez, Marc, Arias-Martinez, Aranzazu, Sauri, Tamara, Martín Carnicero, Alfonso, Mangas, Monserrat, Martín Richard, Marta, Granja, Mónica, Ramchandani, Avinash, Hernández Pérez, Carolina, Cerdá, Paula, Gil-Negrete, Aitziber, Calvo, Mariona, Vidal Tocino, Rosario, and Gallego, Javier

Published
2021
Full Text
View/download PDF

2. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Author

Jiménez-Fonseca, Paula, Carmona-Bayonas, Alberto, Sánchez Lorenzo, Maria Luisa, Plazas, Javier Gallego, Custodio, Ana, Hernández, Raquel, Garrido, Marcelo, García, Teresa, Echavarría, Isabel, Cano, Juana María, Rodríguez Palomo, Alberto, Mangas, Monserrat, Macías Declara, Ismael, Ramchandani, Avinash, Visa, Laura, Viudez, Antonio, Buxó, Elvira, Díaz-Serrano, Asunción, López, Carlos, Azkarate, Aitor, Longo, Federico, Castañón, Eduardo, Sánchez Bayona, Rodrigo, Pimentel, Paola, Limón, Maria Luisa, Cerdá, Paula, Álvarez Llosa, Renata, Serrano, Raquel, Lobera, Maria Pilar Felices, Alsina, María, Hurtado Nuño, Alicia, and Gómez-Martin, Carlos

Published
2017
Full Text
View/download PDF

3. sj-docx-1-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Author

Jimenez-Fonseca, Paula, Foy, Victoria, Raby, Sophie, Carmona-Bayonas, Alberto, Macía-Rivas, Lola, Arrazubi, Virginia, Cacho Lavin, Diego, Hernandez San Gil, Raquel, Custodio, Ana, Cano, Juana María, Fernández Montes, Ana, Mirallas, Oriol, Macias Declara, Ismael, Vidal Tocino, Rosario, Visa, Laura, Limón, María Luisa, Pimentel, Paola, Martínez Lago, Nieves, Sauri, Tamara, Martín Richard, Marta, Mangas, Monserrat, Gil Raga, Mireia, Calvo, Aitana, Reguera, Pablo, Granja, Mónica, Martín Carnicero, Alfonso, Hernández Pérez, Carolina, Cerdá, Paula, Gomez Gonzalez, Lucía, Garcia Navalon, Francisco, Pacheco Barcia, Vilma, Gutierrez Abad, David, Ruiz Martín, Maribel, Weaver, Jamie, Mansoor, Wasat, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

4. sj-docx-3-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Author

Jimenez-Fonseca, Paula, Foy, Victoria, Raby, Sophie, Carmona-Bayonas, Alberto, Macía-Rivas, Lola, Arrazubi, Virginia, Cacho Lavin, Diego, Hernandez San Gil, Raquel, Custodio, Ana, Cano, Juana María, Fernández Montes, Ana, Mirallas, Oriol, Macias Declara, Ismael, Vidal Tocino, Rosario, Visa, Laura, Limón, María Luisa, Pimentel, Paola, Martínez Lago, Nieves, Sauri, Tamara, Martín Richard, Marta, Mangas, Monserrat, Gil Raga, Mireia, Calvo, Aitana, Reguera, Pablo, Granja, Mónica, Martín Carnicero, Alfonso, Hernández Pérez, Carolina, Cerdá, Paula, Gomez Gonzalez, Lucía, Garcia Navalon, Francisco, Pacheco Barcia, Vilma, Gutierrez Abad, David, Ruiz Martín, Maribel, Weaver, Jamie, Mansoor, Wasat, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-3-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

5. sj-docx-5-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Author

Jimenez-Fonseca, Paula, Foy, Victoria, Raby, Sophie, Carmona-Bayonas, Alberto, Macía-Rivas, Lola, Arrazubi, Virginia, Cacho Lavin, Diego, Hernandez San Gil, Raquel, Custodio, Ana, Cano, Juana María, Fernández Montes, Ana, Mirallas, Oriol, Macias Declara, Ismael, Vidal Tocino, Rosario, Visa, Laura, Limón, María Luisa, Pimentel, Paola, Martínez Lago, Nieves, Sauri, Tamara, Martín Richard, Marta, Mangas, Monserrat, Gil Raga, Mireia, Calvo, Aitana, Reguera, Pablo, Granja, Mónica, Martín Carnicero, Alfonso, Hernández Pérez, Carolina, Cerdá, Paula, Gomez Gonzalez, Lucía, Garcia Navalon, Francisco, Pacheco Barcia, Vilma, Gutierrez Abad, David, Ruiz Martín, Maribel, Weaver, Jamie, Mansoor, Wasat, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-5-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

6. sj-docx-2-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Author

Jimenez-Fonseca, Paula, Foy, Victoria, Raby, Sophie, Carmona-Bayonas, Alberto, Macía-Rivas, Lola, Arrazubi, Virginia, Cacho Lavin, Diego, Hernandez San Gil, Raquel, Custodio, Ana, Cano, Juana María, Fernández Montes, Ana, Mirallas, Oriol, Macias Declara, Ismael, Vidal Tocino, Rosario, Visa, Laura, Limón, María Luisa, Pimentel, Paola, Martínez Lago, Nieves, Sauri, Tamara, Martín Richard, Marta, Mangas, Monserrat, Gil Raga, Mireia, Calvo, Aitana, Reguera, Pablo, Granja, Mónica, Martín Carnicero, Alfonso, Hernández Pérez, Carolina, Cerdá, Paula, Gomez Gonzalez, Lucía, Garcia Navalon, Francisco, Pacheco Barcia, Vilma, Gutierrez Abad, David, Ruiz Martín, Maribel, Weaver, Jamie, Mansoor, Wasat, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

7. sj-docx-4-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Author

Jimenez-Fonseca, Paula, Foy, Victoria, Raby, Sophie, Carmona-Bayonas, Alberto, Macía-Rivas, Lola, Arrazubi, Virginia, Cacho Lavin, Diego, Hernandez San Gil, Raquel, Custodio, Ana, Cano, Juana María, Fernández Montes, Ana, Mirallas, Oriol, Macias Declara, Ismael, Vidal Tocino, Rosario, Visa, Laura, Limón, María Luisa, Pimentel, Paola, Martínez Lago, Nieves, Sauri, Tamara, Martín Richard, Marta, Mangas, Monserrat, Gil Raga, Mireia, Calvo, Aitana, Reguera, Pablo, Granja, Mónica, Martín Carnicero, Alfonso, Hernández Pérez, Carolina, Cerdá, Paula, Gomez Gonzalez, Lucía, Garcia Navalon, Francisco, Pacheco Barcia, Vilma, Gutierrez Abad, David, Ruiz Martín, Maribel, Weaver, Jamie, Mansoor, Wasat, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-4-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

8. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Author

Jimenez-Fonseca, Paula, primary, Foy, Victoria, additional, Raby, Sophie, additional, Carmona-Bayonas, Alberto, additional, Macía-Rivas, Lola, additional, Arrazubi, Virginia, additional, Cacho Lavin, Diego, additional, Hernandez San Gil, Raquel, additional, Custodio, Ana, additional, Cano, Juana María, additional, Fernández Montes, Ana, additional, Mirallas, Oriol, additional, Macias Declara, Ismael, additional, Vidal Tocino, Rosario, additional, Visa, Laura, additional, Limón, María Luisa, additional, Pimentel, Paola, additional, Martínez Lago, Nieves, additional, Sauri, Tamara, additional, Martín Richard, Marta, additional, Mangas, Monserrat, additional, Gil Raga, Mireia, additional, Calvo, Aitana, additional, Reguera, Pablo, additional, Granja, Mónica, additional, Martín Carnicero, Alfonso, additional, Hernández Pérez, Carolina, additional, Cerdá, Paula, additional, Gomez Gonzalez, Lucía, additional, Garcia Navalon, Francisco, additional, Pacheco Barcia, Vilma, additional, Gutierrez Abad, David, additional, Ruiz Martín, Maribel, additional, Weaver, Jamie, additional, Mansoor, Wasat, additional, and Gallego, Javier, additional

Published
2023
Full Text
View/download PDF

9. sj-docx-3-tam-10.1177_17588359211019672 – Supplemental material for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Author

Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martinez-Torron, Alba, Alsina, Maria, Custodio, Ana, Serra, Olbia, Cacho Lavin, Diego, Limón, María Luisa, Sauri, Tamara, López, Flora, Visa, Laura, Granja, Mónica, Martínez Lago, Nieves, Arrazubi, Virginia, Vidal Tocino, Rosario, Hernandez, Raquel, Aguado, Gema, Cano, Juana María, Martín Carnicero, Alfonso, Mangas, Monserrat, Pimentel, Paola, Fernández Montes, Ana, Macias Declara, Ismael, Longo, Federico, Ramchandani, Avinash, Martín Richard, Marta, Hurtado, Alicia, Azkarate, Aitor, Hernández Pérez, Carolina, Serrano, Raquel, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-3-tam-10.1177_17588359211019672 for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry by Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López, Laura Visa, Mónica Granja, Nieves Martínez Lago, Virginia Arrazubi, Rosario Vidal Tocino, Raquel Hernandez, Gema Aguado, Juana María Cano, Alfonso Martín Carnicero, Monserrat Mangas, Paola Pimentel, Ana Fernández Montes, Ismael Macias Declara, Federico Longo, Avinash Ramchandani, Marta Martín Richard, Alicia Hurtado, Aitor Azkarate, Carolina Hernández Pérez, Raquel Serrano and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

10. sj-docx-1-tam-10.1177_17588359211019672 – Supplemental material for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Author

Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martinez-Torron, Alba, Alsina, Maria, Custodio, Ana, Serra, Olbia, Cacho Lavin, Diego, Limón, María Luisa, Sauri, Tamara, López, Flora, Visa, Laura, Granja, Mónica, Martínez Lago, Nieves, Arrazubi, Virginia, Vidal Tocino, Rosario, Hernandez, Raquel, Aguado, Gema, Cano, Juana María, Martín Carnicero, Alfonso, Mangas, Monserrat, Pimentel, Paola, Fernández Montes, Ana, Macias Declara, Ismael, Longo, Federico, Ramchandani, Avinash, Martín Richard, Marta, Hurtado, Alicia, Azkarate, Aitor, Hernández Pérez, Carolina, Serrano, Raquel, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359211019672 for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry by Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López, Laura Visa, Mónica Granja, Nieves Martínez Lago, Virginia Arrazubi, Rosario Vidal Tocino, Raquel Hernandez, Gema Aguado, Juana María Cano, Alfonso Martín Carnicero, Monserrat Mangas, Paola Pimentel, Ana Fernández Montes, Ismael Macias Declara, Federico Longo, Avinash Ramchandani, Marta Martín Richard, Alicia Hurtado, Aitor Azkarate, Carolina Hernández Pérez, Raquel Serrano and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

11. sj-docx-2-tam-10.1177_17588359211019672 – Supplemental material for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Author

Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martinez-Torron, Alba, Alsina, Maria, Custodio, Ana, Serra, Olbia, Cacho Lavin, Diego, Limón, María Luisa, Sauri, Tamara, López, Flora, Visa, Laura, Granja, Mónica, Martínez Lago, Nieves, Arrazubi, Virginia, Vidal Tocino, Rosario, Hernandez, Raquel, Aguado, Gema, Cano, Juana María, Martín Carnicero, Alfonso, Mangas, Monserrat, Pimentel, Paola, Fernández Montes, Ana, Macias Declara, Ismael, Longo, Federico, Ramchandani, Avinash, Martín Richard, Marta, Hurtado, Alicia, Azkarate, Aitor, Hernández Pérez, Carolina, Serrano, Raquel, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tam-10.1177_17588359211019672 for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry by Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López, Laura Visa, Mónica Granja, Nieves Martínez Lago, Virginia Arrazubi, Rosario Vidal Tocino, Raquel Hernandez, Gema Aguado, Juana María Cano, Alfonso Martín Carnicero, Monserrat Mangas, Paola Pimentel, Ana Fernández Montes, Ismael Macias Declara, Federico Longo, Avinash Ramchandani, Marta Martín Richard, Alicia Hurtado, Aitor Azkarate, Carolina Hernández Pérez, Raquel Serrano and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

12. sj-docx-4-tam-10.1177_17588359211019672 – Supplemental material for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Author

Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martinez-Torron, Alba, Alsina, Maria, Custodio, Ana, Serra, Olbia, Cacho Lavin, Diego, Limón, María Luisa, Sauri, Tamara, López, Flora, Visa, Laura, Granja, Mónica, Martínez Lago, Nieves, Arrazubi, Virginia, Vidal Tocino, Rosario, Hernandez, Raquel, Aguado, Gema, Cano, Juana María, Martín Carnicero, Alfonso, Mangas, Monserrat, Pimentel, Paola, Fernández Montes, Ana, Macias Declara, Ismael, Longo, Federico, Ramchandani, Avinash, Martín Richard, Marta, Hurtado, Alicia, Azkarate, Aitor, Hernández Pérez, Carolina, Serrano, Raquel, and Gallego, Javier

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-4-tam-10.1177_17588359211019672 for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry by Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López, Laura Visa, Mónica Granja, Nieves Martínez Lago, Virginia Arrazubi, Rosario Vidal Tocino, Raquel Hernandez, Gema Aguado, Juana María Cano, Alfonso Martín Carnicero, Monserrat Mangas, Paola Pimentel, Ana Fernández Montes, Ismael Macias Declara, Federico Longo, Avinash Ramchandani, Marta Martín Richard, Alicia Hurtado, Aitor Azkarate, Carolina Hernández Pérez, Raquel Serrano and Javier Gallego in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

13. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

Author

Jimenez-Fonseca, Paula, primary, Carmona-Bayonas, Alberto, additional, Martínez de Castro, Eva, additional, Custodio, Ana, additional, Pericay Pijaume, Carles, additional, Hernandez, Raquel, additional, Aguado, Gema, additional, Castro Unanua, Natalia, additional, Cano, Juana María, additional, López, Flora, additional, Garrido, Marcelo, additional, Fernández Montes, Ana, additional, Visa, Laura, additional, Sánchez Cánovas, Manuel, additional, Limón, María Luisa, additional, Martínez Lago, Nieves, additional, Pimentel, Paola, additional, Hurtado, Alicia, additional, Azkárate, Aitor, additional, Longo, Federico, additional, Diez, Marc, additional, Arias-Martinez, Aranzazu, additional, Sauri, Tamara, additional, Martín Carnicero, Alfonso, additional, Mangas, Monserrat, additional, Martín Richard, Marta, additional, Granja, Mónica, additional, Ramchandani, Avinash, additional, Hernández Pérez, Carolina, additional, Cerdá, Paula, additional, Gil-Negrete, Aitziber, additional, Calvo, Mariona, additional, Vidal Tocino, Rosario, additional, and Gallego, Javier, additional

Published
2020
Full Text
View/download PDF

14. Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer

Author

Carmona-Bayonas, Alberto, additional, Jimenez-Fonseca, Paula, additional, Garrido, Marcelo, additional, Custodio, Ana, additional, Hernandez, Raquel, additional, Lacalle, Alejandra, additional, Cano, Juana María, additional, Aguado, Gema, additional, Martínez de Castro, Eva, additional, Alvarez Manceñido, Felipe, additional, Macias, Ismael, additional, Visa, Laura, additional, Martín Richard, Marta, additional, Mangas, Monserrat, additional, Sánchez Cánovas, Manuel, additional, Longo, Federico, additional, Iglesias Rey, Leticia, additional, Martínez Lago, Nieves, additional, Martín Carnicero, Alfonso, additional, Sánchez, Ana, additional, Azkárate, Aitor, additional, Limón, María Luisa, additional, Hernández Pérez, Carolina, additional, Ramchandani, Avinash, additional, Pimentel, Paola, additional, Cerdá, Paula, additional, Serrano, Raquel, additional, Gil-Negrete, Aitziber, additional, Marín, Miguel, additional, Hurtado, Alicia, additional, Sánchez Bayona, Rodrigo, additional, and Gallego, Javier, additional

Published
2019
Full Text
View/download PDF

15. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.

Author

Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martinez-Torron, Alba, Alsina, Maria, Custodio, Ana, Serra, Olbia, Cacho Lavin, Diego, Limón, María Luisa, Sauri, Tamara, López, Flora, Visa, Laura, Granja, Mónica, Martínez Lago, Nieves, Arrazubi, Virginia, Vidal Tocino, Rosario, Hernandez, Raquel, Aguado, Gema, Cano, Juana María, Martín Carnicero, Alfonso, and Mangas, Monserrat

Abstract

Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity. Methods: 594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab. Results: The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1–21.0) versus ToGA regimens (7.5, 6.4–8.5), p < 0.001. Patients with HER2-IHC 3+ cancers had higher response rates than those with IHC 2+/FISH+, odds-ratio 1.97 (95% CI, 1.25–3.09). The results achieved with CAPOX–trastuzumab were comparable to those attained with ToGA regimens. FOLFOX–trastuzumab was superior to ToGA schemes in terms of overall survival (OS), with a greater magnitude of effect in IHC 2+/FISH+ tumors (HR 0.47, 0.24–0.92) compared with IHC 3+ (HR 0.69, 0.49–0.96), and in diffuse (HR 0.37, 0.20–0.69) versus intestinal-type tumors (HR 0.76, 0.54–1.06). Conclusion: We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX–trastuzumab in clinical practice and point toward a possible benefit of FOLFOX–trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry

Author

Carmona-Bayonas, Alberto, primary, Jiménez-Fonseca, Paula, additional, Echavarria, Isabel, additional, Sánchez Cánovas, Manuel, additional, Aguado, Gema, additional, Gallego, Javier, additional, Custodio, Ana, additional, Hernández, Raquel, additional, Viudez, Antonio, additional, Cano, Juana María, additional, Martínez de Castro, Eva, additional, Macías, Ismael, additional, Martín Carnicero, Alfonso, additional, Garrido, Marcelo, additional, Mangas, Monserrat, additional, Álvarez Manceñido, Felipe, additional, Visa, Laura, additional, Azkarate, Aitor, additional, Ramchandani, Avinash, additional, Fernández Montes, Ana, additional, Longo, Federico, additional, Sánchez, Ana, additional, Pimentel, Paola, additional, Limón, María Luisa, additional, Arias, David, additional, Cacho Lavin, Diego, additional, Sánchez Bayona, Rodrigo, additional, Cerdá, Paula, additional, and García Alfonso, Pilar, additional

Published
2018
Full Text
View/download PDF

17. On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry

Author

Carmona-Bayonas, Alberto, primary, Jiménez-Fonseca, Paula, additional, Lorenzo, Maria Luisa Sánchez, additional, Ramchandani, Avinash, additional, Martínez, Elena Asensio, additional, Custodio, Ana, additional, Garrido, Marcelo, additional, Echavarría, Isabel, additional, Cano, Juana María, additional, Barreto, Jose Enrique Lorenzo, additional, García, Teresa García, additional, Manceñido, Felipe Álvarez, additional, Lacalle, Alejandra, additional, Cardona, Marta Ferrer, additional, Mangas, Monserrat, additional, Visa, Laura, additional, Buxó, Elvira, additional, Azkarate, Aitor, additional, Díaz-Serrano, Asunción, additional, Montes, Ana Fernández, additional, and Rivera, Fernando, additional

Published
2016
Full Text
View/download PDF

18. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Author

Jiménez-Fonseca, Paula, primary, Carmona-Bayonas, Alberto, additional, Sánchez Lorenzo, Maria Luisa, additional, Plazas, Javier Gallego, additional, Custodio, Ana, additional, Hernández, Raquel, additional, Garrido, Marcelo, additional, García, Teresa, additional, Echavarría, Isabel, additional, Cano, Juana María, additional, Rodríguez Palomo, Alberto, additional, Mangas, Monserrat, additional, Macías Declara, Ismael, additional, Ramchandani, Avinash, additional, Visa, Laura, additional, Viudez, Antonio, additional, Buxó, Elvira, additional, Díaz-Serrano, Asunción, additional, López, Carlos, additional, Azkarate, Aitor, additional, Longo, Federico, additional, Castañón, Eduardo, additional, Sánchez Bayona, Rodrigo, additional, Pimentel, Paola, additional, Limón, Maria Luisa, additional, Cerdá, Paula, additional, Álvarez Llosa, Renata, additional, Serrano, Raquel, additional, Lobera, Maria Pilar Felices, additional, Alsina, María, additional, Hurtado Nuño, Alicia, additional, and Gómez-Martin, Carlos, additional

Published
2016
Full Text
View/download PDF

19. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.

Author

Jiménez Fonseca, Paula, Carmona-Bayonas, Alberto, Hernández, Raquel, Custodio, Ana, Cano, Juana Maria, Lacalle, Alejandra, Echavarria, Isabel, Macias, Ismael, Mangas, Monserrat, Visa, Laura, Buxo, Elvira, Álvarez Manceñido, Felipe, Viudez, Antonio, Pericay, Carles, Azkarate, Aitor, Ramchandani, Avinash, López, Carlos, Martinez de Castro, Eva, Fernández Montes, Ana, and Longo, Federico

Subjects
ANTINEOPLASTIC agents, ANTHRACYCLINES, CELL receptors, CISPLATIN, COMPARATIVE studies, HYDROCARBONS, RESEARCH methodology, MEDICAL cooperation, PROGNOSIS, RESEARCH, STOMACH tumors, EVALUATION research, TREATMENT effectiveness, ACQUISITION of data, ODDS ratio
Abstract

Background: The choice of chemotherapy in HER2-negative gastric cancer is based on centre's preferences and adverse effects profile. No schedule is currently accepted as standard, nor are there any factors to predict response, other than HER2 status. We seek to evaluate whether Lauren type influences the efficacy of various chemotherapies and on patient overall survival (OS).Methods: We have conducted a multicenter study in 31 hospitals. The eligibility criteria include diagnosis of stomach or gastroesophageal junction adenocarcinoma, HER2 negativity, and chemotherapy containing 2-3 drugs. Cox proportional hazards regression adjusted for confounding factors, with tests of 'treatment-by-histology' interaction, was used to estimate treatment effect.Results: Our registry contains 1303 tumours analysable for OS end points and 730 evaluable for overall response rate (ORR). A decrease in ORR was detected in the presence of a diffuse component: odds ratio 0.719 (95% confidence interval (CI), 0.525-0.987), P=0.039. Anthracycline- or docetaxel-containing schedules increased ORR only in the intestinal type. The diffuse type displayed increased mortality with hazard ratio (HR) of 1.201 (95% CI, 1.054-1.368), P=0.0056. Patients receiving chemotherapy with docetaxel exhibited increased OS limited to the intestinal type: HR 0.65 (95% CI, 0.49-0.87), P=0.024, with no increment in OS for the subset having a diffuse component. With respect to progression-free survival (PFS), a significant interaction was seen in the effect of docetaxel-containing schedules, with better PFS limited to the intestinal type subgroup, in the comparison against any other schedule: HR 0.65 (95% CI, 0.50-0.85), P=0.015, and against anthracycline-based regimens: HR 0.64 (95% CI, 0.46-0.88), P=0.046.Conclusions: As a conclusion, in this registry, Lauren classification tumour subtypes predicted survival and responded differently to chemotherapy. Future clinical trials should stratify effect estimations based on histology. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results